Spahis et al. discovered that omega-3 PUFA supplementation decreased ALT and the ALT/AST ratio, while NAFLD patients’ ALP levels were lowered by n-3 PUFA supplementation [29,30]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.